Analyzing Zorevunersen in Phase 3 Registrational Study for Dravet Syndrome: The EMPEROR Trial
Spanning the United Kingdom, the United States, European Union, and Japan, the global phase 3 EMPEROR study of zorevunersen is expected to have a data readout by the end of 2027.
Dravet syndrome (DS) is a severe developmental and epileptic encephalopathy marked by frequent, difficult-to-control seizures and significant cognitive, behavioral, and motor impairments. Most cases of the seizure disorder result from mutations in one copy of the SCN1A gene, causing reduced Nav1.1 protein in brain neurons. Despite available treatment with antiseizure medications (ASMs), over 90% of patients with DS continue to experience seizures.1 Zorevunersen (Stoke Therapeutics, Biogen), an investigational therapy for DS, is designed to upregulate Nav1.1 protein expression from the nonmutant copy of the SCN1A gene to restore physiological Nav1.1 levels.